[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.178.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 357
Citations 0
Invited Commentary
December 2016

Beast of Pulmonary Arterial Hypertension Burden

Author Affiliations
  • 1Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Pulmonary Hypertension Program, University of Michigan, Ann Arbor
JAMA Cardiol. 2016;1(9):1030-1031. doi:10.1001/jamacardio.2016.3829

Pulmonary arterial hypertension (PAH) is an incurable, progressive disease of the pulmonary vasculature that leads to right heart failure and, ultimately, death. Significant advances in our understanding of the pathogenesis and pathobiology of the disease have led to the development of novel therapies that, in turn, have offered improvement in outcomes. However, mortality remains unacceptably high for patients with this disease. In addition, PAH is associated with significant morbidity. Complicated medication delivery and adverse effect profiles, disease progression necessitating hospitalization, and effects on social and emotional functioning all contribute to a high burden of disease. However, while hospitalizations for exacerbations of disease are common and appear to be associated with long-term outcomes in PAH,1 little is known about the characteristics, effect on short-term outcomes, and costs associated with these hospitalizations.

First Page Preview View Large
First page PDF preview
First page PDF preview
×